Signed during the ISPOR UAE Chapter 2026 Conference in Abu Dhabi, the Memorandum of Understanding (MoU) coincides with the launch of Arcera’s breakthrough antibiotic in the UAE, reinforcing the country’s focus on antimicrobial resistance, healthcare innovation, and value-based decision-making.

Abu Dhabi, United Arab Emirates, January 31, 2026 – Arcera Life Sciences (“Arcera”), a global life sciences company headquartered in Abu Dhabi, today announced the signing of a strategic MoU with ISPOR UAE Chapter to advance healthcare innovation in the UAE and the launch of a breakthrough intravenous antibiotic to combat Antimicrobial Resistance (AMR). This is a major milestone in Arcera’s mission to enable patient access to innovative therapies and improve healthcare outcomes.
Continue reading Arcera Life Sciences Drives Healthcare Innovation with Strategic ISPOR UAE Chapter Partnership and Novel Antibiotic Launch to Combat Antimicrobial Resistance in the UAE


